drugset / Trial / NCT00857246
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Phase 2
Completed
30 enrolled
NYU Langone Health
Bristol-Myers Squibb · collabEli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
Timeline
- Start
- 2005-07
- Primary completion
- 2011-09
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |